Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2016

View Archived Issues

Novel MC2 receptor antagonists have different effect on corticosterone response to ACTH in vivo

Tobira Therapeutics and Dong-A enter licensing agreements

ZD-100 effectively lowers blood pressure in first-in-human trial

Biota Pharmaceuticals changes name to Aviragen Therapeutics

Merck & Co. patents IRAK-4 inhibitors

Merck & Co. reports HIF prolyl hydroxylase inhibitors

Arena Pharmaceuticals presents phase Ib results for APD-371

FDA accepts Remoxy NDA for review

Catabasis Pharmaceuticals initiates part B of MoveDMD trial

Positive interim review in ongoing AML WT1 T cell clinical trial

Oncternal Therapeutics receives license to develop ROR1 antibodies

Phase Ia study evaluates Ebola virus vaccination with VRC-EBOADC076-00-VP followed by MVA-EBOZ

FDA advisory committee makes recommendation on rociletinib NDA

Cantabio starts preclinical program for Alzheimer's disease

FDA awards fast track designation to Acura's LTX-04

Vaginal Proellex reduces excessive menstrual bleeding in phase IIb study

FDA accepts for review BLA for house dust mite sublingual allergy immunotherapy

FDA grants approval for phase II trial on Resunab

Calmodulin 2 and 3 mutations linked to infant cardiac arrest

FDA grants orphan drug designation to TGV-Inhalonix's Mul-1867

Cellecta develops approach to improve its CRISPR/Cas9 genome-wide screening plaform

Aortic valve stenosis induced in rabbits to study bisphosphonate effects on calcification

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...